Analyse aandeel UCB

Morningstar is voorzichtig optimistisch dat de groei van UCB op de middellange termijn zal herstellen als nieuwe medicijnen een kritische massa bereiken en de operationele leverage helpen verbeteren. (Engeltalig rapport)

Karen Andersen 23 januari, 2014 | 10:02
Facebook Twitter LinkedIn

INVESTMENT THESIS

With blockbuster drugs Zyrtec and Keppra, UCB has emerged as a major biopharmaceutical player. However, given the patent expiration of its former flagship products, the company has struggled in recent years to fill the gap through acquisitions and developing its pipeline products. We are cautiously optimistic that growth will resume in the midterm as new drugs reach critical mass and help improve operating leverage.

UCB has transformed from a hybrid pharma/chemical firm into a pure-play biopharmaceutical player. By shedding noncore assets, such as its chemical peptides manufacturing business, UCB has slimmed down to focus on its more profitable health-care segment. This increased investment in pharmaceuticals gave rise to the antihistamine Zyrtec and epilepsy medication Keppra. However, those two drugs, which represented roughly half of product sales, have since lost patent protection and the firm has seen its growth and profitability deteriorate because of generic competition.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

Om dit artikel te kunnen lezen, kunt u zich inschrijven als Morningstar Basic Member

Registreer gratis
Facebook Twitter LinkedIn

Effecten genoemd in dit artikel

Naam effectPrijsChange (%)Morningstar Rating
UCB SA98,08 EUR0,78Rating

Over de auteur

Karen Andersen  Guest Author

© Copyright 2021 Morningstar, Inc. Alle rechten voorbehouden.

Voorwaarden        Privacybeleid